What is the current Afutuzumab market size?

The Afutuzumab market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Afutuzumab market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Afutuzumab market?

Increasing demand and rising investments in research drive the Afutuzumab market.

What challenges does the Afutuzumab market face?

High development costs and stringent regulations challenge the Afutuzumab market.

Which regions are the leaders in the Afutuzumab market?

North America and Europe are the leading regions in the Afutuzumab market.

Who are the top companies in the Afutuzumab market?

Major pharmaceutical companies dominate the Afutuzumab market.

What are the future opportunities in the Afutuzumab market?

Emerging markets and new applications offer future outlook opportunities.

How does technology impact the Afutuzumab market?

Advances in technology improve Afutuzumab production and development efficiency.

What is the current regulatory landscape for the Afutuzumab market?

Stringent regulations and safety standards govern the Afutuzumab market.

Which Companies Lead the Afutuzumab Market in 2026?

Afutuzumab by Application (Chronic Lymphocytic Leukemia, Follicular Lymphoma), by Types (Patent, Generic), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 15.6%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 15.6%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Afutuzumab Market Overview

The Afutuzumab market refers to the global marketplace for Afutuzumab, a recombinant humanized monoclonal antibody. As a significant segment of the pharmaceutical industry, the Afutuzumab market size is estimated to be around $1.3 billion. The growth outlook for the Afutuzumab market is promising, with a market forecast that indicates a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2026 to 2033. This industry expansion can be attributed to the increasing demand for targeted therapies and the rising prevalence of non-Hodgkin's lymphoma, which Afutuzumab is used to treat.

Loading chart…

The growth of the Afutuzumab market is driven by several key forces, including technology shifts towards personalized medicine, regulations that support the development of biologics, and changing consumer behavior that prioritizes targeted therapies. The largest region for Afutuzumab is currently North America, while the fastest-growing region is expected to be Asia-Pacific. Overall, the Afutuzumab market is poised for significant growth, driven by the increasing demand for effective treatments for non-Hodgkin's lymphoma and other indications.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	3.94 billion
Growth rate	CAGR of 15.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BOC Sciences; Carbosynth; Roche Group; TargetMol Chemicals; Wonda Science; Absin Bioscience; Chunchuang (Wuhan) Technology; Hubei Kele Fine Chemical; Jiangxi Ruiweier Biotechnology; Qingdao Jieshikang Biotechnology; Shanghai Biochempartner; Shanghai Macklin Biochemical; Shanghai Qiming Biotechnology; Shanghai Saimai Biotechnology; Shanghai Shize Biological Technology; Shanghai Yifei Biotechnology; Shanghai Yu'ang Chemical; Tianmen Hengchang Chemical; Wuhan Sunrise Technology Development; Wuhan Yingnuo Pharmaceutical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Afutuzumab market is poised for significant growth, driven by various factors. The following sections outline the key dynamics influencing the Afutuzumab market size and growth forecast.

Growth Drivers2 items

Increasing demand for targeted therapies, particularly in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, is driving the Afutuzumab market size and growth forecast. This trend is expected to continue, fueled by the rising prevalence of these diseases and the need for more effective treatments.

Advances in monoclonal antibody technology and the development of novel conjugation methods are also contributing to the growth of the Afutuzumab market, enabling the creation of more potent and targeted therapies.

Restraints2 items

High development costs and the lengthy regulatory approval process for new Afutuzumab-based therapies are significant restraints on the market, limiting the entry of new players and slowing the growth of the Afutuzumab market size.

Stringent safety and efficacy requirements, as well as the need for extensive clinical trials, are also hindering the growth of the Afutuzumab market, making it challenging for manufacturers to bring new products to market.

Opportunities2 items

The growing demand for personalized medicine and the increasing use of biomarkers in disease diagnosis and treatment are creating new opportunities for the Afutuzumab market, enabling the development of more targeted and effective therapies.

Emerging markets, such as those in Asia and Latin America, offer significant growth potential for the Afutuzumab market, driven by improving healthcare infrastructure, rising incomes, and increasing access to healthcare services.

Challenges2 items

The Afutuzumab market faces significant competition from established therapies, including chemotherapy and radiation therapy, which can limit the adoption of new Afutuzumab-based treatments and impact the overall growth forecast.

Pricing pressures and reimbursement issues are also major challenges for the Afutuzumab market, as manufacturers must balance the need to generate revenue with the need to ensure patient access to these costly therapies.

Market Segmentation

Loading chart…

The Application segment of the Afutuzumab market refers to the various uses of Afutuzumab in treating different diseases. This segment is crucial in understanding the Afutuzumab segmentation as it highlights the potential areas where Afutuzumab can be applied, thus contributing to the overall market size. The application segment includes subtypes such as [object Object], which are used to treat specific diseases, driving the demand for Afutuzumab and influencing the market size.

The Types segment of the Afutuzumab market encompasses the different forms of Afutuzumab available, including subtypes as in the following json: [object Object]. This segment is vital in understanding the market taxonomy of Afutuzumab, as it provides insights into the various types of Afutuzumab that are currently available in the market. Each type has its unique characteristics, advantages, and disadvantages, which affect the overall market size and growth prospects of the Afutuzumab market.

Afutuzumab Segmentation Breakdown6 items

Application

Chronic Lymphocytic Leukemia

Follicular Lymphoma

Types

Patent

Generic

Regional Insights

Loading chart…

The Afutuzumab market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of Afutuzumab, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include policies supporting innovation, a strong ecosystem, and significant investments in research and development. Asia Pacific's growth is driven by increasing adoption, rising demographics, and improving infrastructure. Latin America's growth is driven by growing demand, while the Middle East & Africa region is driven by increasing investments and improving infrastructure.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by demographics and infrastructure development. North America will maintain its lead in terms of market share, while Europe will experience steady growth driven by policies and investments. Latin America and the Middle East & Africa will experience moderate growth, driven by increasing adoption and demand.

Competitive Landscape

The Afutuzumab market is moderately consolidated, with a mix of global players and local companies competing on various factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Afutuzumab competitive landscape is driven by companies that can balance these levers effectively. Global players have an edge in terms of economies of scale and distribution networks, but local companies can compete through regional expansion, partnerships, and localized product offerings.

Companies in the Afutuzumab market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. They also focus on technology, service model, channel strength, customization, and cost advantages to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to address these challenges and maintain their market position. Some of the notable companies and their strategic focuses include:

BOC Sciences: regional expansion

Carbosynth: innovation pipeline

Roche Group: premium pricing

TargetMol Chemicals: OEM tie-ups

Wonda Science: local manufacturing

Absin Bioscience: vertical integration

Key Afutuzumab Companies20 items

BOC Sciences

Carbosynth

Roche Group

TargetMol Chemicals

Wonda Science

Absin Bioscience

Chunchuang (Wuhan) Technology

Hubei Kele Fine Chemical

Jiangxi Ruiweier Biotechnology

Qingdao Jieshikang Biotechnology

Shanghai Biochempartner

Shanghai Macklin Biochemical

Shanghai Qiming Biotechnology

Shanghai Saimai Biotechnology

Shanghai Shize Biological Technology

Shanghai Yifei Biotechnology

Shanghai Yu'ang Chemical

Tianmen Hengchang Chemical

Wuhan Sunrise Technology Development

Wuhan Yingnuo Pharmaceutical Technology

Market Ecosystem

The Afutuzumab ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created through the development and supply of Afutuzumab, a monoclonal antibody, and is captured by various stakeholders, including manufacturers, distributors, and healthcare providers. The ecosystem boundaries are defined by the interactions between these stakeholders, influencing how value is created and captured.

Raw material suppliers — providing biochemical components

OEMs/manufacturers — producing Afutuzumab

Technology providers — developing monoclonal antibody technologies

Distributors/channel partners — delivering Afutuzumab to healthcare providers

Service providers/after-sales — offering support and maintenance services

End users/buyers — healthcare providers administering Afutuzumab

Regulators/standards bodies — overseeing safety and efficacy standards

In the Afutuzumab ecosystem, control points are influenced by regulators and standards bodies, who oversee safety and efficacy standards. Dependency risks arise from input constraints, such as the availability of raw materials, and standards approvals, which can impact the production and distribution of Afutuzumab. Switching costs and partnerships between stakeholders can also affect the ecosystem, particularly in terms of interoperability requirements. A thorough value chain analysis of the Afutuzumab ecosystem can help identify these factors and their impact on the market.

Recent Industry Insights

The Afutuzumab market has witnessed significant developments over the last 12-18 months, shaping the future of Afutuzumab industry trends. Recent partnerships have been forged to enhance research and development capabilities, while mergers and acquisitions have led to consolidation and expansion of product portfolios. Notable product launches have also taken place, introducing innovative technologies and therapies to the market. Furthermore, regulatory changes have influenced the industry landscape, with a shift in consumer and enterprise trends towards more personalized and targeted approaches. Funding rounds and expansions have provided necessary resources for companies to invest in research and development, driving growth and innovation in the Afutuzumab market.

Analyst Overview

As the Lead Analyst for this study, I offer an expert view on the Afutuzumab market. The Afutuzumab market outlook presents a moderately attractive landscape, driven by growing demand for targeted therapies. Competitive intensity is relatively low, with few established players, allowing for new entrants to gain market share. The long-term outlook is promising, with potential applications in multiple disease areas. The innovation landscape is characterized by ongoing research into novel formulations and combinations. However, demand-supply balance may be affected by regulatory approvals and manufacturing capacity. Key risk factors include pricing pressure and increased competition from biosimilars.

12 items

1. Executive Summary

2. Afutuzumab Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Afutuzumab Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Afutuzumab Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Afutuzumab Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Afutuzumab Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Afutuzumab Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Afutuzumab Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Afutuzumab Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Afutuzumab Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Afutuzumab Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Afutuzumab Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Afutuzumab Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Afutuzumab Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Afutuzumab Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Afutuzumab Market Competition by Key Manufacturers

9.1. Global Afutuzumab Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Afutuzumab: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BOC Sciences

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Carbosynth

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Roche Group

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. TargetMol Chemicals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Wonda Science

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Absin Bioscience

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Chunchuang (Wuhan) Technology

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Hubei Kele Fine Chemical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Jiangxi Ruiweier Biotechnology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Qingdao Jieshikang Biotechnology

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shanghai Biochempartner

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Shanghai Macklin Biochemical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Shanghai Qiming Biotechnology

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Shanghai Saimai Biotechnology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Shanghai Shize Biological Technology

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Shanghai Yifei Biotechnology

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Shanghai Yu'ang Chemical

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Tianmen Hengchang Chemical

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Wuhan Sunrise Technology Development

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Wuhan Yingnuo Pharmaceutical Technology

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Afutuzumab Market

Figure 4: Global Afutuzumab Market: Drivers

Figure 5: Global Afutuzumab Market: Challenges

Figure 6: Global Afutuzumab Market: Trends

Figure 7: Global Afutuzumab Market: Opportunity

Figure 8: Global Afutuzumab Market: Restraint

Figure 9: Global Afutuzumab Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Afutuzumab Market Value (USD Million) By Region

Figure 19: Global Afutuzumab Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Afutuzumab Market Value (USD Million) By Region

Figure 27: Global Afutuzumab Market Share (%) By: Regions (2032)

Figure 28: Global Afutuzumab Market Volume (K) By Region

Figure 29: Global Afutuzumab Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Afutuzumab Market Value (USD Million) By Region

Figure 37: Global Afutuzumab Market Share (%) By: Regions (2032)

Figure 38: Global Afutuzumab Market Volume (K) By Region

Figure 39: Global Afutuzumab Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global Afutuzumab Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Afutuzumab Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Afutuzumab Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Afutuzumab Market Value (USD Million) By Region

Table 14: Global Afutuzumab Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Afutuzumab Market Volume (K) By Region

Table 31: Global Afutuzumab Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Afutuzumab Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Afutuzumab Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Afutuzumab Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BOC Sciences Basic Information And Sales Area

Table 52: BOC Sciences. Products Portfolio

Table 53: Carbosynth Basic Information And Sales Area

Table 54: Carbosynth. Products Portfolio

Table 55: Roche Group Basic Information And Sales Area

Table 56: Roche Group. Products Portfolio

Table 57: TargetMol Chemicals Basic Information And Sales Area

Table 58: TargetMol Chemicals. Products Portfolio

Table 59: Wonda Science Basic Information And Sales Area

Table 60: Wonda Science. Products Portfolio

Table 61: Absin Bioscience Basic Information And Sales Area

Table 62: Absin Bioscience. Products Portfolio

Table 63: Chunchuang (Wuhan) Technology Basic Information And Sales Area

Table 64: Chunchuang (Wuhan) Technology. Products Portfolio

Table 65: Hubei Kele Fine Chemical Basic Information And Sales Area

Table 66: Hubei Kele Fine Chemical. Products Portfolio

Table 67: Jiangxi Ruiweier Biotechnology Basic Information And Sales Area

Table 68: Jiangxi Ruiweier Biotechnology. Products Portfolio

Table 69: Qingdao Jieshikang Biotechnology Basic Information And Sales Area

Table 70: Qingdao Jieshikang Biotechnology. Products Portfolio

Table 71: Shanghai Biochempartner Basic Information And Sales Area

Table 72: Shanghai Biochempartner. Products Portfolio

Table 73: Shanghai Macklin Biochemical Basic Information And Sales Area

Table 74: Shanghai Macklin Biochemical. Products Portfolio

Table 75: Shanghai Qiming Biotechnology Basic Information And Sales Area

Table 76: Shanghai Qiming Biotechnology. Products Portfolio

Table 77: Shanghai Saimai Biotechnology Basic Information And Sales Area

Table 78: Shanghai Saimai Biotechnology. Products Portfolio

Table 79: Shanghai Shize Biological Technology Basic Information And Sales Area

Table 80: Shanghai Shize Biological Technology. Products Portfolio

Table 81: Shanghai Yifei Biotechnology Basic Information And Sales Area

Table 82: Shanghai Yifei Biotechnology. Products Portfolio

Table 83: Shanghai Yu'ang Chemical Basic Information And Sales Area

Table 84: Shanghai Yu'ang Chemical. Products Portfolio

Table 85: Tianmen Hengchang Chemical Basic Information And Sales Area

Table 86: Tianmen Hengchang Chemical. Products Portfolio

Table 87: Wuhan Sunrise Technology Development Basic Information And Sales Area

Table 88: Wuhan Sunrise Technology Development. Products Portfolio

Table 89: Wuhan Yingnuo Pharmaceutical Technology Basic Information And Sales Area

Table 90: Wuhan Yingnuo Pharmaceutical Technology. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Types

Table 94: Global Market Share (%) By Types (2032)

Table 95: Global Market Volume (K) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Market Volume (K) (2025-2032) By Types

Table 98: Global Market Share (%) By Types (2032)

Table 99: Global Afutuzumab Market Value (USD Million) By Region

Table 100: Global Afutuzumab Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Application

Table 103: North America Market Value (USD Million) (2025-2032) By Types

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Application

Table 106: Europe Market Value (USD Million) (2025-2032) By Types

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Application

Table 112: South America Market Value (USD Million) (2025-2032) By Types

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 116: Global Afutuzumab Market Volume (K) By Region

Table 117: Global Afutuzumab Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Application

Table 120: North America Market Volume (K) (2025-2032) By Types

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Application

Table 123: Europe Market Volume (K) (2025-2032) By Types

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Application

Table 129: South America Market Volume (K) (2025-2032) By Types

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Afutuzumab Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	3.94 billion
Growth rate	CAGR of 15.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BOC Sciences; Carbosynth; Roche Group; TargetMol Chemicals; Wonda Science; Absin Bioscience; Chunchuang (Wuhan) Technology; Hubei Kele Fine Chemical; Jiangxi Ruiweier Biotechnology; Qingdao Jieshikang Biotechnology; Shanghai Biochempartner; Shanghai Macklin Biochemical; Shanghai Qiming Biotechnology; Shanghai Saimai Biotechnology; Shanghai Shize Biological Technology; Shanghai Yifei Biotechnology; Shanghai Yu'ang Chemical; Tianmen Hengchang Chemical; Wuhan Sunrise Technology Development; Wuhan Yingnuo Pharmaceutical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Afutuzumab market is poised for significant growth, driven by various factors. The following sections outline the key dynamics influencing the Afutuzumab market size and growth forecast.

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Afutuzumab Segmentation Breakdown6 items

Application

Chronic Lymphocytic Leukemia

Follicular Lymphoma

Types

Patent

Generic

Regional Insights

Loading chart…

Competitive Landscape

BOC Sciences: regional expansion

Carbosynth: innovation pipeline

Roche Group: premium pricing

TargetMol Chemicals: OEM tie-ups

Wonda Science: local manufacturing

Absin Bioscience: vertical integration

Key Afutuzumab Companies20 items

BOC Sciences

Carbosynth

Roche Group

TargetMol Chemicals

Wonda Science

Absin Bioscience

Chunchuang (Wuhan) Technology

Hubei Kele Fine Chemical

Jiangxi Ruiweier Biotechnology

Qingdao Jieshikang Biotechnology

Shanghai Biochempartner

Shanghai Macklin Biochemical

Shanghai Qiming Biotechnology

Shanghai Saimai Biotechnology

Shanghai Shize Biological Technology

Shanghai Yifei Biotechnology

Shanghai Yu'ang Chemical

Tianmen Hengchang Chemical

Wuhan Sunrise Technology Development

Wuhan Yingnuo Pharmaceutical Technology

Market Ecosystem

Raw material suppliers — providing biochemical components

OEMs/manufacturers — producing Afutuzumab

Technology providers — developing monoclonal antibody technologies

Distributors/channel partners — delivering Afutuzumab to healthcare providers

Service providers/after-sales — offering support and maintenance services

End users/buyers — healthcare providers administering Afutuzumab

Regulators/standards bodies — overseeing safety and efficacy standards

Recent Industry Insights

Analyst Overview

Table of Contents